Acute Lymphocytic Leukemia
Acute Lymphocytic Leukemia Market

Acute Lymphocytic Leukemia (ALL) is a type of cancer, which affects the blood and bone marrow. It occurs from young white blood cells known as lymphocytes in the bone marrow, mainly characterized by an overproduction of immature white blood cells, known as lymphoblasts or leukemic blasts.

Acute Lymphocytic Leukemia Epidemiological Segmentation 

The Epidemiological Segmentation of Acute Lymphocytic Leukemia in 7MM from 2017 to 2030 is segmented as:- 

  • Total Incident Cases of Leukemia
  • Total Incident Cases of ALL
  • Total Incident Cases of ALL Segmented by Age and Gender
  • Total Subtype-specific Cases of ALL
  • Total Genetic Mutation-specific Cases of ALL
  • Total Treated Cases of ALL

Acute Lymphocytic Leukemia Epidemiology 

  • The total incident cases of ALL in the 7MM in 2017 were 10,341  
  • ALL affects more males than females.
  • The total incident cases of ALL in 2017 in the United States were 5,816

Acute Lymphocytic Leukemia Market

The market size of ALL in the 7MM in 2017 was USD 1,246 million

Acute Lymphocytic Leukemia Market Drivers

  • Increasing Focus Towards the Development of Targeted Therapies
  • Rising Occurrence of ALL
  • Improvement in the Diagnosis and Awareness
  • Competitive Landscape

Acute Lymphocytic Leukemia Market Barriers

  • Financial Impact
  • Generic Erosion
  • High Rate of Chemo resistance Development

Acute Lymphocytic Leukemia Emerging Drugs

The emerging drugs of the Acute Lymphocytic Leukemia market are 

  • Imbruvica (Ibrutinib)
  • Jakafi (ruxolitinib)
  • Motixafortide (BL-8040)
  • TC-110
  • Lisocabtagene Maraleucel (JCAR017)
  • TBI-1501
  • UCART19
  • Venetoclax
  • NiCord (omidubicel)
  • Eliquis (apixaban)
  • Isatuximab
  • JZP-458 (recombinant Erwinia asparaginase)
  • Vyxeos (Daunorubicin and Cytarabine for Injection
  • Daratumumab
  • ProTmune
  • MB-CART19.1
  • BPX-501 T Cells (rivogenlecleucel; iC9-CAR19 cells)
  • PBCAR0191
  • AUTO1
  • KTE-X19

And many others.  

Acute Lymphocytic Leukemia Key Players

The key players in the Acute Lymphocytic Leukemia market are

  • Pharmacyclics (an AbbVie Company)
  • BioLine Rx
  • TCR2 Therapeutics
  • Bristol-Myers Squibb
  • Takara Bio/Otsuka Pharmaceuticals
  • Servier/Allogene
  • AbbVie and Roche
  • Gamida Cell Ltd.
  • Bristol-Myers Squibb
  • Pfizer
  • Sanofi
  • Jazz Pharmaceuticals
  • Janssen Research & Development
  • Fate Therapeutics
  • MiltenyiBiotec B.V. & Co. KG
  • Bellicum Pharmaceuticals
  • Precision BioSciences/Servier
  • Autolus Limited
  • Gilead Sciences
  • Incyte Corporation
  • Novartis

And many others.